Tagged with M

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME CGT, Real World Evidence & The Patient Experience One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME CAR-T and the Art of Managing Expectations Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME Rendering CGT Genuinely Patient Centric In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers…

InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Marc Boutin Global Head of Patient Engagement, novartis SHARE Share on twitter Share on linkedin “How are you today?” For patients, this question may be a challenge. Honest answers can stop a conversation straight away. I know…

UK The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over 1,000 new jobs at its facilities in Northern Ireland over the next three years.   AstraZeneca to create dedicated Covid…

Germany Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer patients eligible to receive Novartis’ CAR-T therapy in Germany.   There has been a big change in the last few…

Saudi Arabia Medochemie’s Yasser Sabra gives a fascinating insight into the branded generic and value added medicine field today, including why the COVID-19 pandemic could lead to a reappraisal of medicine repurposing. Sabra also touches on the firm’s operations in the Middle East’s biggest market of Saudi Arabia, explaining why the Saudi…

Denmark The BioInnovation Institute (BII) is an initiative from the Novo Nordisk Foundation which aims to support entrepreneurial researchers and early-stage life science start-ups with up to DKK 18 million in founder-friendly funding. CEO Jens Nielsen highlights some of the BII’s milestones and success stories since its formation and Denmark’s progress…

Saudi Arabia As the Saudi pharma market – worth approximately USD 8.2 billion – continues to grow, so does the need for pharma companies to efficiently distribute their medicines inside the Kingdom. Here, we present four of the main trends at play in the Saudi distribution landscape, from market consolidation to centralised…

China Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021.   Since first joining the company back in 2002, Afonso held a variety of roles IT…

Pharma Legal Handbook Regulatory reform in Lithuania – a comprehensive legal overview. Prepared in association with TGS Baltic, a leading law firm in Lithuania, this is an extract from The Pharma Legal Handbook: Baltics, available to purchase here for GBP 99.   1. Are there proposals for reform or significant change to the healthcare system?…

Pharma Legal Handbook All about patents and  trademarks in Lithuanian pharma. Prepared in association with TGS Baltic, a leading law firm in Lithuania, this is an extract from The Pharma Legal Handbook: Baltics, available to purchase here for GBP 99.   1. What are the basic requirements to obtain patent and trademark protection? PATENTS: There…